Author Archives: Tiffany Wise

Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

94% of Test-Phase Responders Achieved Significant Symptom Relief with Zero Serious Device-Related Adverse Events
New Data Suggests 30 Minutes of Daily iSNM Therapy Provides UUI Symptom Relief

SAN JOSE, Calif., March 5, 2026 /PRNewswire/ — Neuspera^® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, announced positive 12-month outcomes¹ from its pivotal trial of the Neuspera SNM System, an integrated sacral neuromodulation (iSNM) device for urinary urge incontinence (UUI). The company also announced new data suggesting just 30 minutes of daily iSNM therapy may provide UUI symptom relief. The findings were presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting, Feb. 27, 2026.

Presented by Andrea Pezzella, MD, URPS, FACOG, Southern Urogynecology Wellness and Aesthetics, the 12-month outcomes data for all 128 implanted patients demonstrated:

94% of test-phase responders achieved at least 50% reduction in urgent urinary incontinence episodes
81% of therapy responders were classified as super-responders with at least 75% reduction in UUI episodes
43% of therapy responders were completely dry with 100% reduction in UUI episodes

The Neuspera system, an ultra-miniaturized, implanted system powered with an external transmitter, is designed to address common shortcomings of conventional SNM, such as battery replacements, infections, and implanted battery-related revision surgeries; these battery-related issues may become more frequent with weight loss associated with widespread GLP-1 agonist use. As anticipated, the Neuspera SNM System maintained an excellent safety profile, with zero serious device-related adverse events (AEs) and zero infections through 12 months. Device-related AEs were rare, generally mild, and resolved quickly, with incident rates of 0-3% for all AE categories.

Dr. Pezzella also presented promising initial data using a reduced therapy regimen of just 30-minute daily stimulation. At one month, all patients experienced UUI episode reductions ranging from 73% to 100%, consistent with outcomes from longer therapy durations in the pivotal trial. Neuspera will present additional data on shorter stimulation durations at the American Urological Association Annual (AUA) Meeting later this year.

“It’s exciting to see the durability of the therapy response over time since sustained effectiveness is ultimately what matters for patients,” said Dr. Pezzella. “Additionally, seeing meaningful clinical benefit with shorter daily stimulation sessions is very encouraging. Reduced therapy time could improve the patient experience while maintaining outcomes, and I look forward to further clinical evaluation of this approach.”

“We are very encouraged by these comprehensive 12-month outcomes and initial data of a reduced therapy regimen,” said David Van Meter, CEO of Neuspera Medical. “Neuspera continues to advance the treatment of urinary urge incontinence by combining the gold-standard efficacy of sacral neuromodulation with an improved safety profile and patient experience compared to traditional systems. We extend our sincere thanks to the investigators and clinical teams across the United States and in Europe whose partnership is helping bring this innovative therapy to patients.”

How Neuspera’s iSNM System Works
Neuspera’s integrated SNM system (iSNM) offers all the capabilities of traditional SNM in a highly advanced form factor. A smart, miniaturized neurostimulator is carefully implanted near the sacral nerve, and therapy is activated using an external disc with a battery worn against the lower back for a daily therapy session. When not in use, the therapy disc charges wirelessly, like a smartphone. This intelligent system supports complex neuromodulation therapy delivery while eliminating complications related to implanted batteries, addressing common patient concerns without compromising performance.^2,3

About Neuspera Medical, Inc.
Neuspera^® Medical, Inc. is a leader in advanced, directionally adaptive energy systems that power tiny medical implants. The company is introducing a new class of neurostimulation technology, starting with the first integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI), approved by the FDA in June 2025. Learn more at neuspera.com and on LinkedIn.

Media Contact: media@capwellcomm.com

References:

Pezzella, Andrea et al. “Neuspera’s Ultra-Miniaturized Sacral Neuromodulation (SNM) System for UUI: 12-Month Outcomes from the SANS-UUI Phase II Study.” SUFU 2026 Winter Meeting Abstracts. Neurourology and Urodynamics, 45(S1), S7-S219.
Bretschneider CE, et al. “Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women”. Int Urogynecol J. 2024 Dec;35(12):2349-2355.
Padron, Osvaldo, et al. “MP30-12 Results of the SANS-UUI, Phase II Study: Safety Outcomes at 6-Months for Patients with OAB Symptoms Using Neuspera’s Ultra-Miniaturized System Compared to the Published Standard of Care.” Journal of Urology 213.5S (2025): e1029.

SOURCE Neuspera Medical

Neuspera Medical Announces Milestone Case of Traditional Sacral Neuromodulation (SNM) System Removed and Replaced With the Company’s Integrated SNM System for Urinary Urge Incontinence

Patient Struggled with SNM Battery Pain and Complications; Reports Full Complication Relief Following Implant of Neuspera’s SNM Therapy

New Patient Registry to Track Outcomes of SNM to iSNM Procedures

SAN JOSE, Calif., Feb. 10, 2026 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced a milestone patient revision from a traditional sacral neuromodulation (SNM) system to the recently FDA-approved Neuspera SNM System, an integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI).

The revision, a follow-up surgery that replaces or repairs an existing implant, was performed at University of Louisville Health (UofL Health) in Kentucky. The patient, a 21-year-old woman, experienced persistent battery discomfort and lead issues after receiving a conventional SNM implant, and a prior surgical revision with the conventional system did not improve her symptoms. After receiving the Neuspera iSNM system, the patient experienced immediate and complete complication relief, according to her surgeon. The case highlights the transformative potential of Neuspera’s technology for patients seeking UUI symptom relief without the chronic pain, surgical risks, and restrictions caused by implanted batteries.

“I was in constant pain from the SNM battery and calling my doctor’s office often. They tried an initial revision with another SNM battery device, and it still made no difference. Pain was negatively affecting my quality of life and making it even hard to get out of bed,” said the patient. “After I received the Neuspera iSNM device, I couldn’t believe the difference. The pain is gone, and I finally have my life back! And now my doctor’s office is calling me to check in, because it’s so strange that they haven’t heard from me.”

“This case demonstrates the impact of Neuspera’s integrated design, resolving pain and complications associated with traditional SNM implanted batteries,” said Dr. Kellen Choi, treating urologist at UofL Health. “It’s rewarding to see patients regain their freedom and confidence so quickly, substantially improving their quality of life. In addition to the many patients who have not had any advanced treatment for their UUI, we also have many more patients in line who have these common complications of traditional SNM who would like to pursue this new option with no trade-off whatsoever in efficacy.”

Traditional Sacral Neuromodulation (SNM) Systems
Sacral neuromodulation (SNM) has long been considered the gold standard for advanced overactive bladder (OAB) therapy, offering significant symptom relief for patients who do not respond to conservative treatments. With marginal advancements in the past 30 years, traditional SNM systems have notable downsides, including the need for implanted lithium-ion batteries that can lead to pocket pain, infections, lead migration, and fractures; additionally, surgical battery replacement will be required up to 2-3 times during a patient’s lifetime depending on age. These complications impact patient quality of life and drive substantial healthcare costs. Scaled across the U.S. healthcare system, these procedures contribute to significant fiscal burden, with revisions and replacements accounting for up to 30% of total SNM-related procedures and costs^1,2 — over $300 million annually.

How Neuspera’s Integrated SNM System Works
Neuspera’s integrated SNM system offers all the capabilities of traditional SNM in a highly advanced form factor. A smart, miniaturized neurostimulator is carefully implanted near the sacral nerve, and therapy is activated using an external disc with a battery worn against the lower back for approximately two hours daily. When not in use, the therapy disc charges wirelessly, like a smartphone. This intelligent system supports complex neuromodulation therapy delivery while eliminating complications related to implanted batteries, addressing common patient concerns without compromising performance.

FDA-approved in June 2025, the Neuspera SNM System matches the gold-standard efficacy of traditional SNM while eliminating implanted batteries. A pivotal study of 128 patients implanted with Neuspera’s iSNM therapy found:

91% of trial period responders achieved at least 50% reduction in urgent leaks at six months
84% of therapy responders were classified as “super responders” with at least 75% improvement
42% of patients who responded were completely dry, with 100% reduction in UUI symptoms

Additional pivotal trial data presented at the 2025 American Urological Association Annual Meeting demonstrated statistically significant reductions in complications such as battery pocket pain and infections compared to traditional SNM systems.³

“This case at UofL Health exemplifies how our design, free of implanted batteries, can restore freedom and confidence for patients limited by traditional SNM,” said Dave Van Meter, chief executive officer of Neuspera Medical. “By addressing these common complications linked to conventional devices, Neuspera is offering an improved option and empowering individuals to reclaim control over their lives.”

Building on this momentum, Neuspera is launching the FREEDOM Registry (Follow-up Revision Experience and Evaluation: Device Outcomes Metrics). This prospective registry will gather patient-reported survey data on experiences, quality of life, pain relief, and satisfaction among people who switch from traditional SNM to Neuspera’s iSNM system, for patients experiencing complications (such as battery pocket pain, infections, or lead issues) and those undergoing battery replacements due to depletion.

For more on the Neuspera iSNM system or the FREEDOM Registry, visit www.neuspera.com.

About Neuspera Medical
Neuspera® Medical, Inc. is a leader in advanced, directionally adaptive energy systems that power tiny medical implants deep within the body. The company is introducing a new class of neurostimulation technology, starting with the first integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI), approved by the FDA in June 2025. Learn more at neuspera.com and on LinkedIn.

Media Contact: media@capwellcomm.com

References:

Bretschneider CE, et al. “Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women”. Int Urogynecol J. 2024 Dec;35(12):2349-2355.
Axonics Modulation Technologies, Inc. Form 10-K for the fiscal year ended October 5, 2018. U.S. Securities and Exchange Commission, 2018. https://www.sec.gov/Archives/edgar/data/1603756/000119312518294804/ d609102ds1.htm#toc609102_9.
Padron, O., et al. “Mp30-12 Results of the Sans-UUI, Phase II Study: Safety Outcomes at 6-Months for Patients With OAB Symptoms Using Neuspera’s Ultra-Miniaturized System Compared to the Published Standard of Care.” Journal of Urology 213.5S (2025): e1029.

SOURCE Neuspera Medical

Neuspera Medical Receives FDA Approval for First Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence

SAN JOSE, Calif., June 18, 2025 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved its integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence (UUI).

Neuspera’s iSNM system offers patients with UUI an alternative to traditional SNM. UUI is a major component of overactive bladder, a condition that affects approximately 1 in 5 women in the U.S. UUI has a major impact on quality of life, driving the demand for more effective and patient-friendly treatment options.

Six-month pivotal trial data showed the Neuspera iSNM device delivers efficacy comparable to established SNM therapies, while eliminating the discomfort, surgical risks, and cosmetic concerns of implanted batteries.^1,2 The Phase II pivotal clinical study of 128 patients implanted with Neuspera’s iSNM therapy found:

84.2% of patients had a 50% or greater reduction in urgent leaks³ – on par with reported rates in recent SNM studies^1,2
84% of patients who responded to treatment were classified as “super responders,” meaning they experienced more than a 75% reduction in UUI symptoms
42% of patients who responded were completely “dry,” with 100% reduction in UUI symptoms
3.5x clinically significant improvement in quality of life with a reduction in voids and urgent episodes

“FDA approval of Neuspera’s iSNM system represents a major advancement for millions of patients with UUI,” said Dr. Howard Goldman, vice-chairman of Urology at the Cleveland Clinic. “For too long, patients have had to weigh the benefits of SNM therapy against real concerns about complications related to implanted batteries and the need for surgeries to replace it. Neuspera’s integrated system provides symptom relief without these additional burdens.”

How Neuspera’s Integrated iSNM Therapy Works
Neuspera’s integrated Sacral Neuromodulation (iSNM) system offers all the capabilities of traditional SNM in a highly advanced form factor. A smart, miniaturized neurostimulator is implanted near the sacral nerve, and therapy is activated using an external disc worn against the lower back for approximately two hours daily. When not in use, the therapy disc charges wirelessly, like a smartphone. This intelligent system supports complex neuromodulation therapy delivery while eliminating complications related to implanted batteries, addressing common patient concerns without compromising performance.

“Neuspera is setting a new standard in UUI therapy with the first integrated SNM system,” said Dave Van Meter, CEO of Neuspera. “Our mission is to remove barriers to care with a smart, patient-centered solution that truly improves quality of life for the millions impacted by UUI. This FDA approval is a proud and meaningful moment for the entire Neuspera team and our clinical partners, whose passion and dedication made it possible.”

About Neuspera Medical
Neuspera^® Medical, Inc. is a leader in advanced, directionally adaptive energy systems that power tiny medical implants deep within the body. The company is introducing a new class of neurostimulation technology, starting with the first integrated sacral neuromodulation (iSNM) system for urinary urge incontinence (UUI), approved by the FDA in June 2025. Learn more at neuspera.com and LinkedIn.

Media Contact: media@capwellcomm.com

References

Axonics Artisan Study: McCrery, Rebecca, et al. “Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.” The Journal of Urology, vol. 203, no. 1, 2020, pp. 185-192.
Medtronic Interstim Micro Study: Goudelocke, Colin, et al. “Evaluation of Clinical Performance and Safety for the Rechargeable InterStim Micro Device in Overactive Bladder Subjects: 6-Month Results from the Global Postmarket ELITE Study.” Neurourology and Urodynamics, vol. 42, no. 4, 2023, pp. 761-769
Neuspera SANS-UUI Study: Padron, Osvaldo et al. “Treatment of OAB Symptoms Using Neuspera’s Ultra-Miniaturized System: 6-Month Results of the SANS-UUI Phase II Study. Presented at: Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2025 Winter Meeting; February 25–March 1, 2025; Palm Springs, CA. Abstract, SUFU 2025.

SOURCE Neuspera Medical

Neuspera Medical Announces Landmark Six-Month Clinical Trial Results for the First Battery-Free Percutaneous Sacral Neuromodulation (pSNM) System for Urgency Urinary Incontinence Management

Pivotal Study Data Show Comparable “Gold Standard” Efficacy to Traditional Sacral Neuromodulation (SNM) Devices – Eliminating Burdens of a Battery Implant

SAN JOSE, Calif., Feb. 26, 2025 /PRNewswire/ — Neuspera^® Medical, Inc., the leading developer of wireless energy technology powering the future of bioelectronic medicine, today announced six-month pivotal clinical trial results showing that the efficacy of its battery-free percutaneous sacral neuromodulation (pSNM) system has comparable efficacy to published rates for traditional sacral neuromodulation (SNM) devices,^1,2 while aiming to offer a significantly better patient experience for the treatment of urgency urinary incontinence (UUI). The landmark results will be presented at the 2025 winter meeting of the Society of Urodynamics Female Pelvic Medicine & Urogenital Reconstruction (SUFU) on March 1, 2025.

In a market that has gradually grown to $1 billion worldwide, despite negligible innovation since its inception in 1997, Neuspera has developed the first wireless, battery-free, ultra-miniaturized percutaneous SNM device for the treatment of UUI. The pSNM approach aims to address the most common complaints reported in patient forums: painful infections around the battery pocket, unwanted battery movement, persistent discomfort, visible bulging, and additional required surgeries for battery replacement.

UUI is a major component of OAB (Overactive Bladder), a condition that affects approximately 300 million people worldwide, including 1 in 5 women in the U.S., and has a major impact on quality of life (QOL), driving the demand for more effective and patient-friendly treatment options.

Results Show Proven Efficacy and Significant UUI Symptom Relief

Six-month data from the Phase II pivotal clinical study of 128 patients implanted with Neuspera’s pSNM therapy found:

84.2% of implanted patients had a 50% or greater reduction in urgent leaks – on par with reported rates in recent SNM studies^1,2
84% of patients who responded to treatment were classified as “super responders,” meaning they experienced more than a 75% reduction in UUI symptoms
42% of patients who responded were completely “dry,” with 100% reduction in UUI symptoms
3.5x clinically significant improvement in QOL, with a reduction in voids and urgent episodes

“These results demonstrate that Neuspera’s pSNM technology provides similar effectiveness to traditional SNM devices while offering an alternative to a traditional implanted battery,” said Dr. Colin Goudelocke, MD, Clinical Investigator and Urologist at Ochsner Health System. “Having options available for our patients is so crucial, and pSNM provides consistent relief from UUI while removing what can be an obstacle for some. I look forward to offering this option to my patients once it receives regulatory approval.”

Beyond Legacy Limitations: Wireless Innovation Modernizes a Proven Therapy

Conventional SNM systems require three surgical steps: 1) implanting the neurostimulation device at the sacral nerve, 2) creating a “pocket” in the buttock tissue to house the Oreo-sized metal battery, and 3) surgically creating a “tunnel” from the lower back to the lower abdomen to connect the implanted stimulation device to its battery. Complications related to the implanted batteries include infection at the battery site, battery flipping and movement, chronic pain, battery visibility, and the need for battery replacement surgeries.

“The pivotal trial results validate the founding vision of Neuspera – that we could revolutionize SNM therapy by eliminating the need for an implanted battery,” said Alexander Yeh, Ph.D, Neuspera Founder and Chief Technology Officer. “Our device offers a transformative alternative to traditional SNM, removing the stigma and burden of an invasive surgical implant and eventual battery replacement surgery.”

How the Battery-Free Wireless Sacral Neuromodulation [pSNM] Therapy Works:

Neuspera’s pSNM system has just two components:
1) an ultra-miniaturized neurostimulator – 100x smaller than traditional SNM devices, and

2) a small external therapy disc.

The mini neurostimulator is implanted percutaneously near the sacral nerve through a tiny 2.3mm canula — requiring no stitches and minimal recovery. Patients activate the therapy by placing the Neuspera disc against their lower back for generally just two hours daily, using a discreet wearable belt compatible with most activities. When not in use, the therapy disc charges wirelessly, like a smartphone. Neuspera’s pSNM eliminates all battery complications and associated body image concerns voiced by many patients.

“Sacral neuromodulation has delivered life-changing symptom relief for decades, but implanted batteries remain a significant limitation,” said Dave Van Meter, Neuspera Executive Chairman. “Neuspera is poised to offer a more patient-friendly solution to the millions of patients waiting for a better option. With FDA approval expected this year, we believe the pSNM technology will establish a new standard in UUI therapy.”

Neuspera submitted its Premarket Approval (PMA) to the FDA in September 2024 and, pending regulatory review, anticipates approval later this year.

About Neuspera Medical
Neuspera^® Medical, Inc. is the leading developer of wireless, directionally adaptive energy systems that power tiny medical implants deep within the body. Their technology is enabling a new class of bioelectronic medicine. The company’s initial innovation is the first battery-free percutaneous sacral neuromodulation (pSNM) device for urgency urinary incontinence (UUI), currently pending FDA approval. Neuspera’s pSNM device stands to expand the $1 billion overactive bladder market by providing a less-invasive, battery-free option to millions more UUI patients within the next 10 years. Learn more at neuspera.com and LinkedIn.

Media Contact
media@capwellcomm.com
949-999-3303

References

Axonics Artisan Study: McCrery, Rebecca, et al. “Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.” The Journal of Urology, vol. 203, no. 1, 2020, pp. 185-192.
Medtronic Interstim Micro Study: Goudelocke, Colin, et al. “Evaluation of Clinical Performance and Safety for the Rechargeable InterStim Micro Device in Overactive Bladder Subjects: 6-Month Results from the Global Postmarket ELITE Study.” Neurourology and Urodynamics, vol. 42, no. 4, 2023, pp. 761-769.

SOURCE Neuspera Medical

Primary Endpoint Results of the Neuspera Phase II SANS UUI Clinical Study SUFU Presentation

The primary endpoint results of the Neuspera Phase II SANS UUI clinical study will be presented during the annual winter meeting of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), February 26 – March 1, 2025, in Rancho Mirage, California. These pivotal trial results will support Neuspera’s FDA PMA submission for U.S. regulatory approval and expand the portfolio of clinical evidence Neuspera is building to ensure insurance coding, coverage, and reimbursement. Our presentation, “Podium #46 – TREATMENT OF OAB SYMPTOMS USING NEUSPERA’S ULTRA-MINIATURIZED SYSTEM: 6-MONTH RESULTS OF THE SANS-UUI PHASE II STUDY” is scheduled for 8:00AM during the OAB/Chemodenervation Podium Session, 7:30-9:00AM on Saturday, March 1^st. The full SUFU program schedule can be viewed online.

Neuspera SANS-UUI Trial Progresses

Trial of SNM device for urinary urgency incontinence progresses.

Check out the information in Urology Times, September 2024.

Volume 52, Number 09, Page 10.

Read the full article here.

Neuspera Featured in MassDevice’s Top 10 Urology Device Stories of the Year

Did you know that this week is Urology Week 2024? To commemorate the occasion, MassDevice published an article on the top 10 urology device stories of 2024 so far and it featured our Series D round!

Neuspera Medical, Inc. Welcomes Bunty Banerjee as Its First Chief Operating Officer

The seasoned life sciences executive will play a key role as the company completes the regulatory process and prepares for commercialization of its Neuspera SNM System

SAN JOSE, Calif., Sept. 12, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System, announced today that Bunty Banerjee has joined the company as its first Chief Operating Officer. He will lead the activities in both research and development, as well as operations, while working closely with all other functions as Neuspera completes the U.S. Food and Drug Administration (FDA) submission for regulatory approval of the Neuspera System to treat OAB symptoms and prepares for commercialization.

“Bunty is joining Neuspera at an incredibly exciting time for the company,” said Steffen Hovard, CEO of Neuspera Medical. “We look forward to his contributions to the team as he deploys valuable skills and insights with the organization.”

The Neuspera SNM System is a discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB). Banerjee joins Neuspera following the company achieving a number of significant milestones:

All implanted patients have completed the 6-month primary endpoint visit in the SANS-UUI pivotal trial. The SANS-UUI multi-center, single-arm clinical study was designed to demonstrate the safety and efficacy of the Neuspera System and gain FDA approval in the U.S.
The closing of its Series D funding round raising $23 million and led by Vertex Ventures HC and Treo Ventures with participation by Action Potential Venture Capital, Windham Capital Partners, Portfolia, Olympus Innovation Ventures, and another strategic investor.

Banerjee is a seasoned life sciences executive with more than 25 years of experience in the medical device industry, holding senior operational leadership positions at Omnicell, Philips Image Guided Therapy, Abbott, and Boston Scientific, which involved the development, commercialization, and scaling of complex medical products. He has served in senior leadership roles in enterprises ranging from early start-ups to Fortune 100 corporations, overseeing operations from pre-clinical to billion-dollar businesses.

“I am absolutely thrilled to join the Neuspera team and contribute to the company’s success at this critical stage,” said Banerjee. “I’m looking forward to being a part of an incredibly innovative team and an amazing technology dedicated to improving the lives of patients with chronic health conditions.”

Banerjee has a Bachelor of Science degree in Electrical Engineering from Jadavpur University, India, and a Master of Science degree in Industrial Management from Clemson University.

The Neuspera System has FDA clearance for treating chronic pain of peripheral nerve origin and is currently an investigational device for treating UUI, a symptom associated with OAB.

About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform is designed to provide patients and physicians with new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life. For more information, please visit www.neuspera.com.

Media Contact:
Shelli Lissick
Bellmont Partners
651-276-6922
shelli@bellmontpartners.com

SOURCE Neuspera Medical Inc.

Neuspera Welcomes Two New Employees

We’re excited to welcome two new members to our Neuspera team: Douglas Sullivan as Supply Chain Director and Jeff Siegel, CPA as Controller. We are grateful to have their expertise on the team as we continue working to improve sacral neuromodulation options for treating OAB!

Strong Media Interest in Neuspera

Neuspera Medical is very excited and grateful for the tremendous interest in our progress towards reinventing sacral neuromodulation for treating OAB. The Neuspera Sacral Neuromodulation System includes innovations designed to significantly impact patient acceptance and satisfaction with this potentially life-changing therapy in a large market that has been largely underserved to date. Our two recent press releases were published by more than 1,000 news outlets around the world! Thank you for helping us spread the word that Neuspera Sacral Neuromodulation is coming! The following is a select sample of the many media outlets that have covered our news in the past two weeks.

Clinical Trials Arena

VC News Daily